supertramp: ".... And in models is far superior to Herceptin, with apparently no safety issues whatsoever."
supertramp: Thanks for pointing out to me that Platinum did drop over 46m shares on market, which naturally did lead to this current - JIMHO, depressed - share-price of IMU (but the share-price is seemingly starting to creep upward slightly now...
Could someone on this IMU HC board that has the information handy/ready please remind me (and all others) about the yearly turnover of Herceptin, which I seem to remember as being quite MASSIVE?! If the profits that are being derived from the sales of Herceptin are also available (which I doubt somewhat), could post that information as well. TIA!
This will give IMU holders - again JIMHO - some kind of clue how much (at least) HER-Vaxx will be valued by competition that does not want to forfeit their current turnover/profit. I am certain that figure will be WAY MORE than the current IMU market-cap, which is still below A$ 80 mio!!
All the best to all IMU holders and buyers.
wasa
Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-90
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
-0.001(2.56%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.8¢ | 3.9¢ | 3.8¢ | $134.8K | 3.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 1738258 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 494405 | 4 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
